{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T10:09:00Z","timestamp":1781258940031,"version":"3.54.1"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T00:00:00Z","timestamp":1633564800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Gilead Sciences, Inc.;Gilead Sciences K.K.; and Galapagos."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,2,28]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To evaluate the efficacy and safety of filgotinib for Japanese patients with rheumatoid arthritis (RA) and limited or no prior methotrexate (MTX) exposure.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Data up to 24\u2009weeks were analysed for 71 Japanese patients from a 52-week global Phase 3 study. Patients with RA and limited or no prior MTX exposure were randomised in a 2:1:1:2 ratio to filgotinib 200\u2009mg plus MTX, filgotinib 100\u2009mg plus MTX, filgotinib 200\u2009mg, or MTX. Maximum MTX dose was 15\u2009mg\/week. Primary endpoint was proportion achieving 20% improvement in American College of Rheumatology criteria (ACR20) at Week 24.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Week 24 ACR20 rates in Japanese patients were 82.6%, 90.9%, 83.3%, and 80.0% for filgotinib 200\u2009mg plus MTX, filgotinib 100\u2009mg plus MTX, filgotinib 200\u2009mg, and MTX, respectively. Greater ACR20 rates with filgotinib vs MTX occurred at Week 2. Greater proportions receiving filgotinib vs MTX achieved DAS28-CRP &amp;lt;2.6 at Weeks 12 and 24. Adverse event rates were comparable across treatments and between the Japanese and overall populations.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>While Week 24 ACR20 rates were similar, filgotinib provided faster responses and higher remission rates vs MTX. In Japanese patients with RA and limited or no prior MTX exposure, filgotinib was generally well tolerated.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/mr\/roab021","type":"journal-article","created":{"date-parts":[[2021,12,15]],"date-time":"2021-12-15T13:46:53Z","timestamp":1639576013000},"page":"273-283","source":"Crossref","is-referenced-by-count":7,"title":["Efficacy and safety of filgotinib alone and in combination with methotrexate in Japanese patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 3)"],"prefix":"10.1093","volume":"32","author":[{"given":"Tatsuya","family":"Atsumi","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine, Hokkaido University, Sapporo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiya","family":"Tanaka","sequence":"additional","affiliation":[{"name":"The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsukasa","family":"Matsubara","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, Matsubara Mayflower Hospital, 944-25 Fujita, Kato, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Amano","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Hidaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Ishiguro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Sugiyama","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunihiro","family":"Yamaoka","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Sagamihara, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9","family":"Westhovens","sequence":"additional","affiliation":[{"name":"Department of Development and Regeneration, Skeletal Biology and Engineering Research Centre, Division of Rheumatology, University Hospitals KU Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel W.T","family":"Ching","sequence":"additional","affiliation":[{"name":"Timaru Medical Specialists Limited, South Canterbury, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osvaldo Daniel","family":"Messina","sequence":"additional","affiliation":[{"name":"Investigaciones Reumatologicas y Osteologicas SRL IRO, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd R","family":"Burmester","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Charit\u00e9\u2014University Medicine Berlin, Free University and Humboldt University, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrix","family":"Bartok","sequence":"additional","affiliation":[{"name":"Gilead Sciences Inc., Foster City, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alena","family":"Pechonkina","sequence":"additional","affiliation":[{"name":"Gilead Sciences Inc., Foster City, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Kondo","sequence":"additional","affiliation":[{"name":"Gilead Sciences K.K., Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoyu","family":"Yin","sequence":"additional","affiliation":[{"name":"Gilead Sciences Inc., Foster City, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Guo","sequence":"additional","affiliation":[{"name":"Gilead Sciences Inc., Foster City, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal","family":"Tasset","sequence":"additional","affiliation":[{"name":"Galapagos NV, Mechelen, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John S","family":"Sundy","sequence":"additional","affiliation":[{"name":"Gilead Sciences Inc., Foster City, CA, USA"},{"name":"Department of Medicine, Duke University Medical Center, Durham, NC, USA"},{"name":"Aichi Developmental Disability Center, Kasugai, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,10,7]]},"reference":[{"key":"2022030105113818400_R1","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1056\/NEJMra1004965","article-title":"The pathogenesis of rheumatoid arthritis","volume":"365","author":"McInnes","year":"2011","journal-title":"N Engl J Med"},{"key":"2022030105113818400_R2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/acr.22783","article-title":"2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2022030105113818400_R3","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2022030105113818400_R4","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1080\/14397595.2018.1472358","article-title":"Japan College of Rheumatology guideline for the use of methotrexate in patients with rheumatoid arthritis","volume":"29","author":"Kameda","year":"2019","journal-title":"Mod Rheumatol"},{"key":"2022030105113818400_R5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14397595.2019.1660028","article-title":"A large observational cohort study of rheumatoid arthritis, IORRA: providing context for today\u2019s treatment options","volume":"30","author":"Yamanaka","year":"2020","journal-title":"Mod Rheumatol"},{"key":"2022030105113818400_R6","first-page":"1","article-title":"Clinical aspects in patients with rheumatoid arthritis complicated with lymphoproliferative disorders without regression after methotrexate withdrawal and treatment for arthritis after regression of lymphoproliferative disorders","volume":"31","author":"Nakano","year":"2020","journal-title":"Mod Rheumatol"},{"key":"2022030105113818400_R7","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1093\/rheumatology\/kez213","article-title":"Effectiveness of different combinations of DMARDs and glucocorticoid bridging in early rheumatoid arthritis: two-year results of CareRA","volume":"58","author":"Stouten","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"2022030105113818400_R8","doi-asserted-by":"crossref","first-page":"523","DOI":"10.7326\/M15-0919","article-title":"Long-term outcomes of patients with recent-onset rheumatoid arthritis after 10 years of tight controlled treatment: a randomized trial","volume":"164","author":"Markusse","year":"2016","journal-title":"Ann Intern Med"},{"key":"2022030105113818400_R9","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1136\/annrheumdis-2015-207511","article-title":"The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression","volume":"75","author":"Atsumi","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2022030105113818400_R10","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.3899\/jrheum.110054","article-title":"Abatacept plus methotrexate provides incremental clinical benefits versus methotrexate alone in methotrexate-naive patients with early rheumatoid arthritis who achieve radiographic nonprogression","volume":"38","author":"Wells","year":"2011","journal-title":"J Rheumatol"},{"key":"2022030105113818400_R11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2015.10.003","article-title":"Treatment of rheumatoid arthritis: unraveling the conundrum","volume":"65","author":"Zampeli","year":"2015","journal-title":"J Autoimmun"},{"key":"2022030105113818400_R12","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2147\/JIR.S35901","article-title":"Clinical utility of the oral JAK inhibitor tofacitinib in the treatment of rheumatoid arthritis","volume":"6","author":"Cutolo","year":"2013","journal-title":"J Inflamm Res"},{"key":"2022030105113818400_R13","doi-asserted-by":"crossref","first-page":"i17","DOI":"10.1093\/rheumatology\/key225","article-title":"Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis","volume":"58","author":"Taylor","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"2022030105113818400_R14","doi-asserted-by":"crossref","first-page":"i27","DOI":"10.1093\/rheumatology\/key256","article-title":"Clinical efficacy of new JAK inhibitors under development. Just more of the same?","volume":"58","author":"Westhovens","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"2022030105113818400_R15","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1056\/NEJMoa1310476","article-title":"Tofacitinib versus methotrexate in rheumatoid arthritis","volume":"370","author":"Lee","year":"2014","journal-title":"N Engl J Med"},{"key":"2022030105113818400_R16","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/art.39953","article-title":"Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment","volume":"69","author":"Fleischmann","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2022030105113818400_R17","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.4049\/jimmunol.1201348","article-title":"Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases","volume":"191","author":"Van Rompaey","year":"2013","journal-title":"J Immunol"},{"key":"2022030105113818400_R18","volume-title":"Japanese Package Insert","author":"Jyseleca\u00ae (Filgotinib maleate tablets)","year":"2020"},{"key":"2022030105113818400_R19","volume-title":"Summary of Product Characteristics","author":"Jyseleca\u00ae (filgotinib) 100\u2009mg film-coated tablets","year":"2020"},{"key":"2022030105113818400_R20","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1136\/annrheumdis-2016-210105","article-title":"Filgotinib (GLPG0634\/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2)","volume":"76","author":"Kavanaugh","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2022030105113818400_R21","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1136\/annrheumdis-2016-210104","article-title":"Filgotinib (GLPG0634\/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1)","volume":"76","author":"Westhovens","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2022030105113818400_R22","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1136\/annrheumdis-2020-219214","article-title":"Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial","volume":"80","author":"Combe","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2022030105113818400_R23","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1001\/jama.2019.9055","article-title":"Effect of filgotinib vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy: the FINCH 2 randomized clinical trial","volume":"322","author":"Genovese","year":"2019","journal-title":"JAMA"},{"key":"2022030105113818400_R24","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1136\/annrheumdis-2020-219213","article-title":"Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial","volume":"80","author":"Westhovens","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2022030105113818400_R25","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2022030105113818400_R26","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","article-title":"American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis","volume":"38","author":"Felson","year":"1995","journal-title":"Arthritis Rheum"},{"key":"2022030105113818400_R27","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/art.1780380107","article-title":"Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis","volume":"38","author":"Prevoo","year":"1995","journal-title":"Arthritis Rheum"},{"key":"2022030105113818400_R28","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/art.1780230202","article-title":"Measurement of patient outcome in arthritis","volume":"23","author":"Fries","year":"1980","journal-title":"Arthritis Rheum"},{"key":"2022030105113818400_R29","first-page":"789","article-title":"The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales","volume":"9","author":"Fries","year":"1982","journal-title":"J Rheumatol"},{"key":"2022030105113818400_R30","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection","volume":"30","author":"Ware","year":"1992","journal-title":"Med Care"},{"key":"2022030105113818400_R31","doi-asserted-by":"crossref","DOI":"10.1186\/1477-7525-1-79","article-title":"The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation","volume":"1","author":"Webster","year":"2003","journal-title":"Health Qual Life Outcomes"},{"key":"2022030105113818400_R32","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.1002\/art.22943","article-title":"Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients","volume":"56","author":"Aletaha","year":"2007","journal-title":"Arthritis Rheum"},{"key":"2022030105113818400_R33","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1002\/acr.22824","article-title":"Unraveling patient-preferred health and treatment outcomes in early rheumatoid arthritis: a longitudinal qualitative study","volume":"68","author":"van der Elst","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2022030105113818400_R34","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1080\/14397595.2017.1392057","article-title":"Efficacy and safety of baricitinib in Japanese patients with rheumatoid arthritis: subgroup analyses of four multinational phase 3 randomized trials","volume":"28","author":"Tanaka","year":"2018","journal-title":"Mod Rheumatol"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/32\/2\/273\/42644862\/roab021.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roab021\/41781678\/roab021.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/32\/2\/273\/42644862\/roab021.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T05:12:48Z","timestamp":1646111568000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/32\/2\/273\/6382545"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,7]]},"references-count":34,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,10,7]]},"published-print":{"date-parts":[[2022,2,28]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/roab021","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,3,1]]},"published":{"date-parts":[[2021,10,7]]}}}